3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
8
Phase 2
3
Phase 4
2
Phase 3
1
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Conditions
Neoplasms
3
Nausea
3
Vomiting
2
Multiple Myeloma
2
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pain, Postoperative
1
Pain
1
Neuralgia
1
Lung Neoplasms
1
Leukemia, Biphenotypic, Acute
1
Intestinal Diseases
1
Inflammatory Bowel Diseases
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Digestive System Diseases
1
Crohn Disease
1
Colorectal Neoplasms
1
Interventions
Aprepitant
8
Palonosetron
6
Dexamethasone
6
Granisetron
3
fosaprepitant
2
dexamethasone 21-phosphate
2
Tropisetron
2
Ondansetron
2
Metoclopramide
2
Calcium Dobesilate
2
ramosetron
1
naldemedine
1
gamma-Aminobutyric Acid
1
dolasetron
1
dexamethasone acetate
1
alizapride
1
Tablets
1
Spinal Puncture
1
Saline Solution
1
Population Groups
1
Olanzapine
1
Myelography
1
Duration of Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 4
×
Vomiting
×
Calcium Dobesilate
×
Clear all
NCT01636947
2018-09-25
KMEC
Merck Sharp & Dohme LLC
Phase 4
Completed
494 enrolled
14 charts
NCT01913990
2017-01-30
ER11-02
Ottawa Hospital Research Institute
Phase 4
Unknown
323 enrolled